NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $34.50 Consensus Target Price from Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned an average rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $34.50.

NRXP has been the subject of several analyst reports. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Ascendiant Capital Markets upped their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a report on Monday, April 27th. D. Boral Capital reiterated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Finally, Wall Street Zen cut NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $3.33 on Friday. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The firm has a market cap of $144.19 million, a price-to-earnings ratio of -6.05 and a beta of 2.18. The company has a fifty day moving average price of $3.77 and a 200-day moving average price of $2.99.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Monday, August 17th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. On average, research analysts anticipate that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Large investors have recently modified their holdings of the stock. Anson Funds Management LP grew its position in shares of NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter worth about $994,000. Bleakley Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter worth about $318,000. AdvisorShares Investments LLC boosted its stake in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after purchasing an additional 92,463 shares during the period. Finally, Vanguard Group Inc. boosted its stake in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after purchasing an additional 82,781 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.